Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris, Robert L; Blumenschein, George; Fayette, Jerome; Guigay, Joel; Colevas, A Dimitrios; Licitra, Lisa; Harrington, Kevin J; Kasper, Stefan; Vokes, Everett E; Even, Caroline; Worden, Francis; Saba, Nabil F; Docampo, Lara Carmen Iglesias; Haddad, Robert; Rordorf, Tamara; Kiyota, Naomi; Tahara, Makoto; Lynch, Mark; Jayaprakash, Vijayvel; Li, Li; Gillison, Maura L

Ferris, Robert L; Blumenschein, George; Fayette, Jerome; Guigay, Joel; Colevas, A Dimitrios; Licitra, Lisa; Harrington, Kevin J; Kasper, Stefan; Vokes, Everett E; Even, Caroline; Worden, Francis; Saba, Nabil F; Docampo, Lara Carmen Iglesias; Haddad, Robert; Rordorf, Tamara; Kiyota, Naomi; Tahara, Makoto; Lynch, Mark; Jayaprakash, Vijayvel; Li, Li; Gillison, Maura L.

Afiliación

Ferris RL; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: ferrisrl@upmc.edu.
Blumenschein G; MD Anderson Cancer Center, Houston, TX, USA.
Fayette J; Centre Leon Berard, Lyon, France.
Guigay J; Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, Nice, France.
Colevas AD; Stanford University, Stanford, CA, USA.
Licitra L; Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.
Harrington KJ; Royal Marsden NHS Foundation Trust/The Institute of Cancer Research National Institute of Health Research Biomedical Research Centre, London, UK.
Kasper S; West German Cancer Center, University Hospital, Essen, Germany.
Vokes EE; University of Chicago Medical Center, Chicago, IL, USA.
Even C; Gustave Roussy, Villejuif Cedex, France.
Worden F; University of Michigan, Ann Arbor, MI, USA.
Saba NF; Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Docampo LCI; Hospital Universitario 12 de Octubre, Madrid, Spain.
Haddad R; Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
Rordorf T; Universitätsspital Zurich, Zurich, Switzerland.
Kiyota N; Kobe University Hospital, Kobe, Japan.
Tahara M; National Cancer Center Hospital East, Kashiwa, Japan.
Lynch M; Bristol-Myers Squibb, Princeton, NJ, USA.
Jayaprakash V; Bristol-Myers Squibb, Princeton, NJ, USA.
Li L; Bristol-Myers Squibb, Princeton, NJ, USA.
Gillison ML; MD Anderson Cancer Center, Houston, TX, USA.

Oral Oncol ; 81: 45-51, 2018 06.

Article en En | MEDLINE | ID: mdl-29884413

Asunto(s)

Antineoplásicos Inmunológicos/uso terapéutico; Antígeno B7-H1/metabolismo; Metástasis de la Neoplasia; Recurrencia Local de Neoplasia; Nivolumab/uso terapéutico; Carcinoma de Células Escamosas de Cabeza y Cuello/tratamiento farmacológico; Análisis de Supervivencia; Antineoplásicos Inmunológicos/efectos adversos; Humanos; Nivolumab/efectos adversos; Carcinoma de Células Escamosas de Cabeza y Cuello/patología

Palabras clave

CD274 protein, human (PD-L1 Protein, Human); Carcinoma, squamous cell of head and neck; Clinical Trial, Phase III; Head and Neck Neoplasms; Immunotherapy; Nivolumab; Papillomaviridae (HPV, Human Papillomavirus Viruses); Programmed Cell Death 1 Receptor; Survival Analysis; Survivors (Long-term Survivors)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Análisis de Supervivencia / Antígeno B7-H1 / Antineoplásicos Inmunológicos / Carcinoma de Células Escamosas de Cabeza y Cuello / Nivolumab / Metástasis de la Neoplasia / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Oral Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google